Home / Pharmaceuticals / Listeria Monocytogenes Infections Treatment Market By Type Of Infection (Bacteremia, Meningitis, Brain Abscess, Gastroenteritis, Endocarditis, Pipeline Analysis) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Listeria Monocytogenes Infections Treatment Market By Type Of Infection (Bacteremia, Meningitis, Brain Abscess, Gastroenteritis, Endocarditis, Pipeline Analysis) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: May 2016 | Report Code: 57831-05-16

This report on global Listeria monocytogenes infections treatment market studies various drugs used for treatment of Listeria monocytogenes infection’s along with pipeline analysis of upcoming potential drugs. According to Centers for Disease Control and Prevention (CDC), Listeriosis, a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes, is an important public health problem in the United States. In addition, CDC estimates that approximately 1600 illnesses and 260 deaths due to listeriosis occur annually in the United States. Thus, drug pipeline of Listeria monocytogenes infections treatment market comprises potential drugs which are more target-specific and possess innovative properties. 

For the purpose of this study, the various infection types studied include bacteremia, meningitis, brain abscess, gastroenteritis, endocarditis, and others. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

 

Listeria Monocytogenes Infections Treatment Market

The pipeline analysis for Listeria monocytogenes infections treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global Listeria monocytogenes infections treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Listeria monocytogenes Infections Treatment Market Portaiture
2.2 Global Listeria monocytogenes Infections Treatment Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Listeria monocytogenes Infections Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Listeria monocytogenes Infections Treatment Market: Market Dynamics and Outlook
3.1 Listeria monocytogenes Infections Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Listeria monocytogenes Infections Treatment Market, 2015 (Value %)

Chapter 4 Global Listeria monocytogenes Infections Treatment Market, By Type of Infection
4.1 Preface
4.2 Bacteremia
4.3 Meningitis
4.4 Brain Abscess
4.5 Gastroenteritis
4.6 Endocarditis
4.7 Others
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Carbavance
4.8.1.2 Telavancin
4.8.1.3 Daptomycin
4.8.1.4 Prulifloxacin
4.8.1.5 DTaP-IPV/Hib combined vaccine
4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Listeria Monocyogenes Infections Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Merck & Co.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
v.3.4 News Coverage
6.4 Astra Zeneca plc
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Johnson & Johnson Limited
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Abbott Laboratories
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly and Company
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Sanofi SA
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Medimmune
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Baxter International, Inc.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures

FIG. 1 Global Listeria monocytogenes Infections Treatment Market, by Type of Infection, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Listeria monocytogenes Infections Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Listeria monocytogenes Infections Treatment Market, 2015
FIG. 4 Market Share Analysis: Global Listeria monocytogenes Infections Treatment Market, 2015 (Value %)
FIG. 5 Global Bacteremia Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG. 6 Global Meningitis Market of Listeria monocytogenes Infections Treatment, 20137– 2022 (USD Mn)
FIG. 7 Global Brain Abscess Market of Listeria monocytogenes Infections Treatment, 2013 –2022 (USD Mn)
FIG. 8 Global Gastroenteritis Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG. 9 Global Endocarditis Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG. 10 Global Others Market of Listeria monocytogenes Infections Treatment, 2013 – 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global Carbavance Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global Telavancin Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Daptomycin Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 14 Pipeline Analysis: Global Prulifloxacin Market for Listeria monocytogenes Infections Treatment , Upto 2022 (USD Mn)
FIG 15 Pipeline Analysis: Global DTaP-IPV/Hib combined vaccine Market for Listeria monocytogenes Infections , Upto 2022 (USD Mn)
FIG 16 Global U.S. Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 17 Global Canada Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 18 Global U.K Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 19 Global Germany Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 20 Global Rest of Europe Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 21 Global China Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 22 Global Japan Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 23 Global Rest of Asia Pacific Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 24 Global Latin America Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 25 Global Middle East and Africa Listeria monocytogenes Infections Treatment Market Revenue, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Listeria monocytogenes Infections Treatment Market Revenue, by Type of Infection, 2013 – 2022 (USD Mn)
TABLE 2 Global Listeria monocytogenes Infections Treatment Market Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Listeria monocytogenes Infections Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Listeria monocytogenes Infections Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia - Pacific Listeria monocytogenes Infections Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Rest of the World Listeria monocytogenes Infections Treatment Market Revenue, by Region, 2013 – 2022 (USD Mn)

Type of Infection Segmentation Analysis

In 2010, a study carried out by European researchers published in the World Health Organization’s (WHO) The Lancet Infectious Diseases suggested that, Listeria monocytogenes was estimated to infect 23,150 people worldwide and killed 5,463 of them, or 23.6 percent.  According to market experts, Listeria causes significantly fewer deaths worldwide than Salmonella Typhi (216,500 annual deaths) or non-typhoidal Salmonella (155,000), but it does cause a far higher rate of death.

Based on the infection type, the Listeria monocytogenes infections treatment market is segmented into:

  • Bacteremia
  • Meningitis
  • Brain Abscess
  • Gastroenteritis
  • Endocarditis
  • Others

Listeria Monocytogenes Infections Treatment Market


Listeriosis is a serious, potentially fatal infection caused by Listeria species. Listeria species are found throughout the environment, residing in soil, water, sewage, vegetation, wild animal feces, farms, and food-processing facilities. In year 2015 it was observed that Bacteremia and Meningitis were the most prevalent diseases in the world, the major factors assisting the market growth were rise in prevalence of foodborne diseases, unawareness in case of personal and environmental sanitation in developing and developed countries, and improper cleaning and processing of vegetables and meat products. According to Centers for Disease Control and Prevention (CDC), Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. The incidence and case-fatality rates for bacterial meningitis vary by region, country, pathogen, and age group. Without treatment, the case-fatality rate can be as high as 70%, and one in five survivors of bacterial meningitis may be left with permanent squealed including hearing loss, neurologic disability, or loss of a limb.

For the purpose of this study, the global Listeria monocytogenes infections treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Listeria Monocytogenes Infections Treatment Market

North America was observed as the largest market for Listeria monocytogenes infections treatment in the base year 2015. Despite strict regulatory policies, L. monocytogenes still has a major detrimental influence in the food industry, causing food product recalls and disease outbreaks. According to a report published by United States Department of Agriculture (USDA) suggests that, every year approximately 48 million people become ill from foodborne illnesses in the United States. Even though just 1,600 people, on average, are sickened by foodborne Listeria, it ranks 3rd among causes of foodborne illness-associated deaths in the United States, causing nearly 19% of such deaths (255 in a typical year). It imposes an estimated USD 2.8 billion in economic burden in a typical year of which almost USD 2.1 billion is due to deaths. Rising prevalence of foodborne diseases, low grade sanity conditions at manufacturing site, improper storage and transportation of food materials and low awareness associated with the foodborne diseases in under developed and developing countries are the key factors assisting the market growth of Listeria monocytogenes infections treatment market globally during the forecast period 2016 – 2022.  

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients